Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Braunwald E, Saberi S, Abraham TP, Elliott PM, et al. Eur Heart J 2023;44:4622-4633.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Braunwald E, Saberi S, Abraham TP, Elliott PM, et al. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J 2023;44:4622-4633.
PMID: 37804245